How much total funding has ASEMtech secured in its entire Series A round as of March 2026?

Combined with the 250 million yen raised in April 2025, ASEMtech has achieved a total of 400 million yen in funding for the entire Series A round.

What regulatory authorization has ASEMtech obtained for its medical device development?

ASEMtech has obtained a Class II Medical Device Marketing Authorization, strengthening its regulatory application and quality management systems.

ASEMtech Raises 150 Million Yen in Series A Extension Round

Q: What company raised 150 million yen in a Series A extension round in March 2026?

ASEMtech Co., Ltd. raised 150 million yen through a third-party allotment of shares in a Series A extension round conducted in March 2026.

Q: Which financial institutions participated in ASEMtech's Series A extension round?

Participants in the Series A extension round include Hanno Shinkin Bank, Tama Shinkin Bank, BP Capital Co., Ltd. (TUAT Fund No. 1), and Leo Denshi Co., Ltd.

Q: What milestone did ASEMtech achieve regarding clinical research with its medical device prototype?

ASEMtech completed a medical device prototype and began clinical research targeting musculoskeletal disorders at university hospitals using the ASEM method.

Published Apr 3, 2026 1:10 AM ・ Updated Jun 17, 2026 11:21 AM ・ 10 min read ・ Source: PR TIMES

ASEMtech, a company developing Acoustically Stimulated Electromagnetic (ASEM) technology, has raised 150 million yen in a Series A extension round, bringing its total Series A funding to 400 million yen. The funds will accelerate clinical research for medical applications, regulatory approval processes, and the expansion of its industrial non-destructive testing business.

Accelerating clinical research, regulatory affairs, and overseas expansion for social implementation in medical and industrial fields

ASEMtech Co., Ltd. (Headquarters: Koganei, Tokyo; Representative Directors: Kenji Ikushima, Nobuo Niimi; hereinafter "ASEMtech"), which aims for the social implementation of the Acoustically Stimulated Electromagnetic (ASEM) method—a technology that visualizes electricity and magnetism using ultrasound—has raised a total of 150 million yen through a third-party allotment of shares in a Series A extension round conducted in March 2026. Combined with the 250 million yen raised in the Series A round in April 2025, the company has achieved a total of 400 million yen in funding for the entire Series A round.

Participants in this round include Hanno Shinkin Bank, Tama Shinkin Bank, BP Capital Co., Ltd. (TUAT Fund No. 1), and Leo Denshi Co., Ltd.

Initiatives Accelerated by This Funding

With this funding, ASEMtech will further promote the following key advancements in both the medical and industrial sectors:

1. Completion of Prototype and Commencement of Clinical Research at University Hospitals

A medical device prototype using the ASEM method has been completed, and clinical research targeting musculoskeletal disorders has begun at university hospitals. This marks the start of full-scale clinical utility verification for the world's first technology capable of non-invasively visualizing the accumulation and orientation of collagen fibers.

2. Acquisition of Class II Medical Device Marketing Authorization

The company has strengthened its organizational structure for regulatory applications and has obtained a Class II Medical Device Marketing Authorization. This represents a significant step forward in the development and quality management systems required for market launch as a medical device.

3. Commencement of Discussions for Overseas Expansion with Singaporean Medical Institutions

To facilitate the international deployment of the ASEM method, the company has begun discussions regarding joint research and clinical implementation with medical institutions in Singapore. It is building a foundation for overseas expansion to meet medical needs in the Asian region.

4. Full-Scale Launch of Industrial Non-Destructive Testing Business and Product Sales in Steel, Materials, and Infrastructure Sectors

The industrial non-destructive testing equipment developed during the seed stage has already begun sales for applications in steel and material inspection and infrastructure maintenance, establishing it as a viable business. Moving forward, the company will focus on expanding its customer base and strengthening its product lineup in the industrial sector to meet the diverse needs of client companies.

Comment from Kenji Ikushima, Representative Director of ASEMtech Co., Ltd.

ASEMtech aims to provide innovative solutions in the medical, healthcare, and industrial fields, centered on the "ASEM method," a technology that visualizes electricity and magnetism using ultrasound.

In this funding round, we were joined by new investors Hanno Shinkin Bank and Tama Shinkin Bank, and received additional investment from existing investors BP Capital and Leo Denshi. With the support of these regional financial institutions, we will further strengthen our collaboration with companies in the Tama and West Saitama areas, accelerating the creation of value as a cutting-edge technology originating from the region.

Taking this funding as an opportunity, we will further accelerate clinical research targeting musculoskeletal disorders, begin full-scale preparations for regulatory approval as a medical device, and actively promote the market deployment of industrial non-destructive testing equipment for steel inspection and infrastructure maintenance.

Our mission is to contribute to the "extension of healthy life expectancy" and the "realization of a safe and secure society." We are committed to accelerating the social implementation of our innovative technology while continuing to advance our research and development. We will continue to strive to meet everyone's expectations.

About ASEMtech Co., Ltd.

[Company Overview]

Company Name: ASEMtech Co., Ltd.

Headquarters: Room 106, University Research Administration Center (URAC), Tokyo University of Agriculture and Technology Koganei Campus, 2-24-16 Nakamachi, Koganei, Tokyo 184-0012

Representative Director, President & CEO: Kenji Ikushima

Vice President: Nobuo Niimi

Business Description: Research, development, design, manufacturing, sales, and leasing of medical application equipment related to the ASEM method

Research, development, design, manufacturing, sales, and leasing of industrial non-destructive testing equipment related to the ASEM method

Established: November 2023

Website: https://asem-tech.com/

FACT BOX

Source: PR TIMES
Category: financial

ASEMtech Raises 150 Million Yen in Series A Extension Round

⚡ Key Points

FACT BOX

Editorial & Verification Standards

FAQ

Cite this article — HOW TO CITE

AI CRAWLER ACTIVITY